Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, tyrosine kinase inhibitors such as dasatinib and bosutinib exhibiting SFK-inhibitory actions show pre-clinical activity in AML models,22 and are approved in chronic myeloid leukemia (CML).23”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
La Rosée, P., Martiat, P., Leitner, A., Klag, T., Müller, M. C., Erben, P., Schenk, T., Saussele, S., & Hochhaus, A. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1769-2 · Cited by 50
Research works printed but not linked: 81
- Hochhaus, 2017, Long-term outcomes of imatinib treatment for chronic myeloid leukemia, N Engl J Med., 376, 917, 10.1056/NEJMoa1609324 · DOI · Paper page
- Sasaki, 2015, Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials, Lancet Haematol., 2, e186, 10.1016/S2352-3026(15)00048-4 · DOI · Paper page
- Mughal, 2016, Chronic myeloid leukemia: reminiscences and dreams, Haematologica., 101, 541, 10.3324/haematol.2015.139337 · DOI
- Baccarani, 2017, Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence, Leukemia., 31, 1015, 10.1038/leu.2017.20 · DOI
- Baccarani, 2013, European leukemianet recommendations for the management of chronic myeloid leukemia: 2013, Blood., 122, 872, 10.1182/blood-2013-05-501569 · DOI · Paper page
- Kantarjian, 2002, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N Engl J Med., 346, 645, 10.1056/NEJMoa011573 · DOI · Paper page
- O'Brien, 2003, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med., 348, 994, 10.1056/NEJMoa022457 · DOI · Paper page
- Gugliotta, 2015, Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia, Haematologica., 100, 1146, 10.3324/haematol.2015.129221 · DOI
- Viganò, 2014, First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis, Am J Hematol., 89, E184, 10.1002/ajh.23804 · doi:10.1002/ajh.23804
- Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med., 344, 1031, 10.1056/NEJM200104053441401 · DOI · Paper page
- Liu, 2016, Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: an updated meta-analysis, J Cancer Res Ther., 12, 23, 10.4103/0973-1482.191623 · doi:10.4103/0973-1482.191623
- Cortes, 2010, Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia, J Clin Oncol Off J Am Soc Clin Oncol., 28, 398, 10.1200/JCO.2009.25.4920 · DOI · Paper page
- Kantarjian, 2012, Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION), Blood., 119, 1123, 10.1182/blood-2011-08-376087 · DOI · Paper page
- Naqvi, 2018, Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia, Cancer., 124, 2740, 10.1002/cncr.31357 · DOI · Paper page
- Rosti, 2009, Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia, Blood., 114, 4933, 10.1182/blood-2009-07-232595 · DOI · Paper page
- Cortes, 2010, Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase, J Clin Oncol Off J Am Soc Clin Oncol., 28, 392, 10.1200/JCO.2009.25.4896 · DOI · Paper page
- Saglio, 2010, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia, N Engl J Med., 362, 2251, 10.1056/NEJMoa0912614 · DOI · Paper page
- Hochhaus, 2016, Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial, Leukemia., 30, 1044, 10.1038/leu.2016.5 · DOI · Paper page
- Konig, 2008, Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606, Blood., 111, 2329, 10.1182/blood-2007-05-092056 · DOI
- Cortes, 2011, Safety and efficacy of bosutinib (SKI-606) in chronic phase philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib, Blood., 118, 4567, 10.1182/blood-2011-05-355594 · DOI · Paper page
- Khoury, 2012, Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure, Blood., 119, 3403, 10.1182/blood-2011-11-390120 · DOI · Paper page
- Cortes, 2012, Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial, J Clin Oncol Off J Am Soc Clin Oncol., 30, 3486, 10.1200/JCO.2011.38.7522 · DOI · Paper page
- Cortes, 2018, Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial, J Clin Oncol Off J Am Soc Clin Oncol., 36, 231, 10.1200/JCO.2017.74.7162 · DOI · Paper page
- Gugliotta, 2013, Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors, Expert Rev Hematol., 6, 563, 10.1586/17474086.2013.837279 · DOI
- Sacha, 2017, A multicenter prospective study on efficacy and safety of imatinib generics: a report from polish adult leukemia group imatinib generics registry, Am J Hematol., 92, E125, 10.1002/ajh.24748 · doi:10.1002/ajh.24748
- Claudiani, 2018, The argument for using imatinib in CML, Hematol Am Soc Hematol Educ Program., 2018, 161, 10.1182/asheducation-2018.1.161 · DOI · Paper page
- Breccia, 2016, Early molecular response in chronic myeloid leukemia and halving time: latest evidences, Leuk Res., 48, 20, 10.1016/j.leukres.2016.06.010 · doi:10.1016/j.leukres.2016.06.010
- Radich, 2018, Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology, J Natl Compr Cancer Netw JNCCN., 16, 1108, 10.6004/jnccn.2018.0071 · DOI · Paper page
- Hochhaus, 2018, Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol., 10.1093/annonc/mdy159 · doi:10.1093/annonc/mdy159
- Saglio, 2018, Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient-physician perspective, Clin Lymphoma Myeloma Leuk., 18, 375, 10.1016/j.clml.2018.04.005 · DOI
- Hijiya, 2019, How I treat chronic myeloid leukemia in children and adolescents, Blood., 133, 2374, 10.1182/blood.2018882233 · DOI
- Cortes, 2019, Treatment-free remission with first- and second-generation tyrosine kinase inhibitors, Am J Hematol., 94, 346, 10.1002/ajh.25342 · DOI · Paper page
- Fava, 2019, Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice, Haematologica., 10.3324/haematol.2018.205054 · DOI · Paper page
- Shah, 2014, Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study, Blood., 123, 2317, 10.1182/blood-2013-10-532341 · DOI · Paper page
- Giles, 2013, Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study, Leukemia., 27, 107, 10.1038/leu.2012.181 · DOI · Paper page
- Gambacorti-Passerini, 2018, Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study, Haematologica., 103, 1298, 10.3324/haematol.2017.171249 · DOI
- Tiribelli, 2018, Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients, Oncotarget., 9, 14219, 10.18632/oncotarget.24478 · DOI
- Cortes, 2018, Dasatinib versus imatinib in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: dascern study, Blood., 132, 788, 10.1182/blood-2018-99-111978 · doi:10.1182/blood-2018-99-111978
- Cortes, 2016, Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial, Lancet Haematol., 3, e581, 10.1016/S2352-3026(16)30167-3 · DOI
- Garcia-Gutierrez, 2016, Safety and efficacy of dasatinib treatment change for patients previosly treated with imatinib with late warning response. Results from the phase II, open, multicenter dasapost study, Blood., 128, 5450, 10.1182/blood.V128.22.5450.5450 · doi:10.1182/blood.v128.22.5450.5450
- Hughes, 2017, Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results, Leukemia., 31, 2529, 10.1038/leu.2017.247 · DOI
- Rea, 2016, ENESTPath: a phase 3 study to assess the effect of nilotinib treatment duration on treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CMLCP) previously treated with imatinib: 24-month. Analysis of the first 300 patients in the induction/consolidation phase, Blood., 128, 3094, 10.1182/blood.V128.22.3094.3094 · doi:10.1182/blood.v128.22.3094.3094
- Cortes, 2016, Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study, Clin Lymphoma Myeloma Leuk., 16, 286, 10.1016/j.clml.2016.02.002 · DOI
- Hiwase, 2018, Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the phase IIIb ENESTswift study, Leuk Res., 67, 109, 10.1016/j.leukres.2018.02.013 · DOI
- Cortes, 2011, Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib, Blood., 117, 5600, 10.1182/blood-2010-11-318949 · DOI
- Gambacorti Passerini, 2018, Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with philadelphia chromosome–positive (Ph+) leukemia: phase 1/2 study update, J Clin Oncol Off J Am Soc Clin Oncol., 36, 7062, 10.1200/JCO.2018.36.15_suppl.7062 · doi:10.1200/jco.2018.36.15_suppl.7062
- Giles, 2010, Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy, Leukemia., 24, 1299, 10.1038/leu.2010.110 · DOI · Paper page
- Cortes, 2016, Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib, Am J Hematol., 91, 1206, 10.1002/ajh.24536 · DOI · Paper page
- García-Gutiérrez, 2019, Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients, Ann Hematol., 98, 321, 10.1007/s00277-018-3507-2 · DOI
- Cortes, 2013, A phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias, N Engl J Med., 369, 1783, 10.1056/NEJMoa1306494 · DOI · Paper page
- Cortes, 2018, Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial, Blood., 132, 393, 10.1182/blood-2016-09-739086 · DOI · Paper page
- Jain, 2016, Analysis of 2013 european leukaemianet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes, Br J Haematol., 173, 114, 10.1111/bjh.13936 · DOI
- Lipton, 2015, Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors, Leuk Res., 39, 58, 10.1016/j.leukres.2014.10.005 · DOI
- Breccia, 2018, Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice, Ann Hematol., 97, 1577, 10.1007/s00277-018-3337-2 · doi:10.1007/s00277-018-3337-2
- Tefferi, 2018, Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia, Hematol Oncol., 36, 718, 10.1002/hon.2517 · DOI
- Iurlo, 2018, Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option, Clin Drug Investig., 38, 475, 10.1007/s40261-018-0623-7 · doi:10.1007/s40261-018-0623-7
- Levy, 2019, Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison, Curr Med Res Opin., 35, 479, 10.1080/03007995.2018.1510225 · doi:10.1080/03007995.2018.1510225
- Cerveira, 2018, Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report, BMC Cancer., 18, 1229, 10.1186/s12885-018-5100-4 · doi:10.1186/s12885-018-5100-4
- Kantarjian, 2011, Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial, Lancet Oncol., 12, 841, 10.1016/S1470-2045(11)70201-7 · DOI · Paper page
- Apperley, 2015, Chronic myeloid leukaemia, Lancet Lond Engl., 385, 1447, 10.1016/S0140-6736(13)62120-0 · DOI · Paper page
- Steegmann, 2016, European leukemianet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia, Leukemia., 30, 1648, 10.1038/leu.2016.104 · DOI · Paper page
- Sakurai, 2019, Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia, Int J Hematol., 109, 292, 10.1007/s12185-019-02596-z · DOI
- Cortes, 2017, Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management, Clin Lymphoma Myeloma Leuk., 17, 78, 10.1016/j.clml.2016.09.012 · DOI
- Hughes, 2019, Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for philadelphia chromosome-positive leukemia, Haematologica., 104, 93, 10.3324/haematol.2018.188987 · DOI
- Rousselot, 2014, Dasatinib daily dose optimization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized OPTIM DASATINIB trial, Haematologica., 99, 237
- Iurlo, 2018, Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life italian multicenter series, Ann Hematol., 97, 95, 10.1007/s00277-017-3144-1 · DOI
- Montani, 2012, Pulmonary arterial hypertension in patients treated by dasatinib, Circulation., 125, 2128, 10.1161/CIRCULATIONAHA.111.079921 · DOI · Paper page
- Weatherald, 2017, Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study, Eur Respir J., 50, 10.1183/13993003.00217-2017 · DOI
- Iurlo, 2015, Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?, Oncotarget., 6, 33944, 10.18632/oncotarget.5580 · DOI
- Cortes, 2016, Long-term evaluation of cardiac and vascular toxicity in patients with philadelphia chromosome-positive leukemias treated with bosutinib, Am J Hematol., 91, 606, 10.1002/ajh.24360 · DOI · Paper page
- Cortes, 2017, Effects of bosutinib treatment on renal function in patients with philadelphia chromosome-positive leukemias, Clin Lymphoma Myeloma Leuk., 17, 684, 10.1016/j.clml.2017.06.001 · DOI
- Jain, 2019, Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs, Blood Adv., 3, 851, 10.1182/bloodadvances.2018025874 · DOI
- Caocci, 2019, Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the systematic coronary risk evaluation (SCORE) chart, Hematol Oncol., 10.1002/hon.2606 · DOI
- Heiblig, 2018, Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study, Exp Hematol., 67, 41, 10.1016/j.exphem.2018.08.006 · DOI
- Kwak, 2017, Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia, Clin Cancer Res Off J Am Assoc Cancer Res., 23, 7180, 10.1158/1078-0432.CCR-17-0957 · DOI · Paper page
- Au, 2009, Chronic myeloid leukemia in Asia, Int J Hematol., 89, 14, 10.1007/s12185-008-0230-0 · DOI
- Horikoshi, 2003, Effects of lower dose of imatinib to CML patients, Leuk Res., 27, 1167, 10.1016/S0145-2126(03)00101-2 · doi:10.1016/s0145-2126(03)00101-2
- Eadie, 2018, The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro, Oncotarget., 9, 13423, 10.18632/oncotarget.24393 · DOI
- Schoepfer, 2018, Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1, J Med Chem., 61, 8120, 10.1021/acs.jmedchem.8b01040 · DOI · Paper page
- Hughes, 2016, Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of 619 BCR-ABL, reveals significant and durable responses in patients with CML-chronic phase with 620 failure of prior TKI therapy, Blood., 128, 625, 10.1182/blood.V128.22.625.625 · DOI
- Rea, 2018, Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial, Blood., 132, 792, 10.1182/blood-2018-99-113609 · DOI
Cited by
Specchia, G., Pregno, P., Breccia, M., Castagnetti, F., Monagheddu, C., Bonifacio, M., Tiribelli, M., Stagno, F., Caocci, G., Martino, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739171 · Cited by 21
Cortes, J. E., Lang, F., Rea, D., Hochhaus, A., Breccia, M., Goh, Y. T., Heinrich, M. C., Hughes, T. P., Janssen, J. J. W. M., le Coutre, P., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02592-9 · Cited by 16
Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia
Hu, X., Li, L., Nkwocha, J., Kmieciak, M., Shang, S., Cowart, L. A., Yue, Y., Horimoto, K., Hawkridge, A., Rijal, A., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02125-x · Cited by 15
Metadata
- Authors
- García-Gutiérrez, V., & Hernández-Boluda, J. C.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-03
- Volume
- 9
- ISSN
- 2234-943X
- Cited by
- 134
- References
- 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. https://app.cochat.ai/papers/10.3389/fonc.2019.00603
- The paper
- García-Gutiérrez, V., & Hernández-Boluda, J. C. (2019). Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. Frontiers in Oncology. https://doi.org/10.3389/fonc.2019.00603
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.